萊茵生物(002166.SZ):擬2880萬元購買甜菊糖微生物酶轉化相關技術和資產
格隆匯11月3日丨萊茵生物(002166.SZ)公吿稱,公司結合自身行業特點和優勢,擬逐步加大合成生物學技術應用於公司主營的天然、健康功能性成分領域的投入,進一步提升公司綜合競爭優勢。
1、設立合成生物學相關技術應用的全資子公司
公司擬出資人民幣5000萬元設立一家合成生物技術應用相關的全資子公司(簡稱“新公司”,具體名稱以市場監督管理部門核准登記為準)。新公司將主要圍繞天然甜味劑等公司核心產品領域相關的生物合成技術產業化能力建設,開展新產品、新技術的成果轉化和投資,致力於將新公司打造成為國內領先的天然甜味劑領域生物合成技術成果轉化基地。
2、購買甜菊糖微生物酶轉化相關技術和資產
為拓展公司甜菊糖產品的工藝路線,進一步提升公司在甜菊糖產品應用領域的客户服務能力,公司擬以人民幣2880萬元的總價購買江蘇施宇甜生物科技有限公司(簡稱“施宇甜”)擁有的甜菊糖微生物酶轉化工藝技術等全部知識產權(包括但不限於國內外專利、商標、認證等)及相關設備資產,並與其簽訂了《關於甜菊糖微生物酶轉化工藝技術及設備資產的轉讓協議》。預計全部資產的交付週期為12個月。
該項工藝技術的初始來源為中國科學院微生物研究院,施宇甜經過多年的工藝完善升級和大生產驗證,現已具備較好的規模化生產基礎。
3、新增發酵生產車間建設
為充分保證擬收購資產的產業化落地,並進一步提升其生產規模,公司擬新建一個發酵生產車間(第一期),並與公司的分離、純化等提取相關工序進行配套。這將有助於該項收購資產更快速的發揮協同效應,提升資產收益率。經初步測算,該期發酵生產車間的投入預計約4000萬元(不含該次轉讓涉及的設備資產),預計建設週期為12個月,具體投資金額屆時以實際投入為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.